Second, we evaluated the anti‐HCC effects of two other CDK4/6 inhibitors, ribociclib (LEE011; Novartis, Basel, Switzerland) and abemaciclib (LY‐2835219; Eli Lilly, Indianapolis, IN, USA), which have recently reached early clinical trials (Geoffrey Shapiro et al., 2013; Jeffrey Infante et al., 2014). This evidence concerns the gene CDK4 and hepatocellular carcinoma.